covid-19-vaccines

Documents about covid-19-vaccines

• NVX-CoV2372, monovalent mRNA and bivalent mRNA vaccines elicit broadly cross-reactive antibodies against emerging SARS-CoV-2 variants#253545Europe PMC
• Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a#832748ClinicalTrials.gov
• Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance#363592ClinicalTrials.gov
• Suspicion of Hypoglycemic Effect of mRNA Based Covid-19 Vaccines (Polyethylene Glycol) Will Happen , Observational Study on Diabetic Patients at Saudia Arabia#181730ClinicalTrials.gov
• Effectiveness of COVID-19 Vaccines Against the SARS-COV-2 Delta (B.1.617.2)#914321ClinicalTrials.gov
• COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older#290850ClinicalTrials.gov
• Behavioural and Social Drivers (BeSD) of COVID-19 vaccination for children: A cross-sectional study of parental vaccine confidence and intent in Mysore, India#18907PLOS
• Impact of the vaccination against SARS-CoV-2 campaign on disproportionality indicator from the WHO pharmacovigilance database: A competition bias study from case/non-case analysis#676855HAL (France)
• Does mRNA-based COVID-19 vaccination in the subacute phase lead to microstructural brain changes? A prospective pilot MRI study using T1 relaxometry#273288Europe PMC
• The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients#185593IRIS
• Compare Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine#969158ClinicalTrials.gov
• Factors associated with severe COVID-19 outcomes among adults with at least a primary vaccination schedule: A retrospective cohort study from Alberta, Canada#461601PLOS
• Feuille de route de l’OMS concernant l’utilisation des vaccins contre la COVID-19 dans le contexte des variants Omicron et d’une forte immunité collective : approche visant à optimiser l’impact mondial des vaccins contre la COVID-19 alors que le variant Omicron et ses sous-lignées sont les principaux variants préoccupants en circulation, compte tenu des objectifs de santé publique, de l’évolution épidémiologique et d’une immunité collective croissante, première publication : 20 octobre 2020, mise à jour : 13 novembre 2020, mise à jour : 16 juillet 2021, mise à jour : 21 janvier 2022, mise à jour : 30 mars 2023, dernière mise à jour : 10 novembre 2023#341846WHO IRIS
• Hoja de ruta de la OMS sobre el uso de las vacunas contra la COVID-19 en el contexto de la variante ómicron y de la elevada inmunidad de la población: criterio para optimizar el impacto mundial de las vacunas contra la covid-19 en un momento en que la variante ómicron y sus sublinajes son las variantes preocupantes dominantes en circulación, sobre la base de los objetivos de salud pública, las características epidemiológicas en evolución y la creciente inmunidad de la población, primera publicación: 20 de octubre de 2020, actualización: 13 de noviembre de 2020, actualización: 16 de julio de 2021, actualización: 21 de enero de 2022, actualización: 30 de marzo de 2023, actualización: 10 de noviembre de 2023#341849WHO IRIS
• mRNA vaccines and therapeutics beyond COVID-19: A review of the global clinical development landscape, low- and middle-income countries involvement and relevance to their contexts#4586Europe PMC